Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Media Campaign On Dietary Supplements Urged At Stakeholder Meeting

This article was originally published in The Tan Sheet

Executive Summary

A more focused FDA consumer education campaign using additional media resources would help consumers learn about the potential risks associated with dietary supplement intake, Joyce Lashof, MD, University of California at Berkeley, said at an agency stakeholder meeting in Oakland, Calif. July 20.

You may also be interested in...



Formal Supplement Advisory Committee Not Necessary, NNFA's Ford Tells FDA

A voluntary advisory committee combining academia, consumer groups, industry, Congress and FDA would help the agency through some of the "issues" where it needs "assistance" in developing a strategic plan for dietary supplement regulation under the Dietary Supplement Health & Education Act, National Nutritional Foods Association President Michael Ford said at an FDA stakeholder meeting in Washington, D.C. June 8.

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

In Brief

Combe sells most of its OTC brands

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS090103

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel